纳武利尤单抗治疗肾细胞癌骨转移的疗效与安全性:GETUG-AFU26-NIVOREN多中心II期研究结果
NIVOREN是一项多中心前瞻性研究,评估抗血管生成药物治疗失败后接受纳武利尤单抗治疗的肾细胞癌患者。入组720例患者中194例存在骨转移,骨转移患者中位总生存期17.9个月,校正后差异未达统计学显著(p=0.0707),中位无进展生存期在校正后仍较短(2.8个月对4.6个月,p=0.0045),客观缓解率较低(14.8%对23.3%)。36%骨转移患者发生骨骼相关事件,事后分析显示骨靶向药物与骨骼相关事件发生率降低相关(OR=0.367,95%CI 0.151-0.895)。
要点
- 骨转移患者中位无进展生存期在校正后仍较短(2.8个月对4.6个月,p=0.0045),客观缓解率较低(14.8%对23.3%)。
- 骨转移患者中位总生存期17.9个月对26.1个月(p=0.0023),校正后差异未达统计学显著(p=0.0707)。
- 36%骨转移患者发生骨骼相关事件,事后分析显示骨靶向药物与骨骼相关事件发生率降低相关(OR=0.367,95%CI 0.151-0.895)。
核心结论
- 纳武利尤单抗治疗肾细胞癌骨转移患者与较短的无进展生存期和较低的客观缓解率相关。
- 研究提示骨靶向药物联合免疫治疗可降低骨骼相关事件的发生率。
研究设计与样本
- NIVOREN是一项多中心前瞻性研究,纳入抗血管生成药物治疗失败后接受纳武利尤单抗治疗的肾细胞癌患者。
- 本研究纳入入组时存在骨转移的全部患者,共194例,来自接受纳武利尤单抗治疗的720例患者。
- 主要终点为总生存期,次要终点包括无进展生存期、客观缓解率、安全性和骨骼相关事件。
主要发现
- 中位随访时间为23.9个月。
- 骨转移患者中位总生存期为17.9个月,无骨转移患者为26.1个月(p=0.0023),校正后差异未达统计学显著(p=0.0707)。
- 骨转移患者中位无进展生存期在校正后仍较短(2.8个月对4.6个月,p=0.0045)。
- 骨转移患者客观缓解率为14.8%,无骨转移患者为23.3%。
- 36%的骨转移患者发生骨骼相关事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone metastatic RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial. MATERIALS AND METHODS: All patients with BM at inclusion were included in our study. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE). RESULTS: Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The median follow-up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post-hoc analysis evaluating the impact of bone-targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895]). CONCLUSION: Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE.
引用
- Velev M, Dalban C, Chevreau C, et al. Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study. Eur J Cancer. 2023. PMID: 36746010. doi:10.1016/j.ejca.2022.12.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。